After obtaining the clinical trial approval issued by SFDA, it is expected that the transfer price of the clinical approval of cryptoalgae is more than 25 million yuan, and the investment company can choose to transfer the shares at this time to withdraw. It will take about 4 years to complete the clinical trial and obtain the new drug certificate, and the price of transferring the new drug certificate is expected to be more than 100 million yuan.

|||At present, peptide drugs on the market in China include thymopentin, thymosin A1, somatostatin, octreotide, salmon calcitonin, lipin, glutathione, oxytocin, etc. The dosage form of polypeptide drugs only limits the cost reduction. However, due to the high cost of peptide synthesis, it is not feasible to make it into tablets and other easy-to-use dosage forms.

Therefore, at present, almost all polypeptide varieties are freeze-dried powder injection, which has many objective reasons. As for the prospect of polypeptide drugs, at present, parents in law have their own reasons. However, in view of the rapid development of bioengineering drugs, the peak period of peptide drugs is far from coming.

As for the claim that polypeptides are not suitable for making drugs, there is a large market among researchers of traditional chemical drugs, especially those of "small molecule" drug chemistry.

For example, for the research of antimicrobial peptides, many people have a negative attitude. But what will happen in the future depends on the future development. It seems incomplete to discuss this issue in isolation here. |||It's very professional. Please ask the biomedical experts to help. You can also consult the relevant research institutes.
|||Cryptoalgin C-1, a new small polypeptide for the treatment of drug-resistant solid tumors, is a small polypeptide drug for the treatment of drug-resistant solid tumors screened and isolated from cyanobacteria by the University of Hawaii. This compound, especially its derivatives, can distinguish cancer cells from normal cells, thus selectively killing cancer cells.

In the in vivo experiment, some derivatives of cryptoalgin are much better than all the anticancer drugs in clinical use (such as paclitaxel, adriamycin, vinblastine, camptothecin, etoposide, etc.). NSF, NIH, NCI and other units have provided long-term and large amount of special fund support for this research, and relevant research progress and results have also passed the formal regular review of various expert groups organized by these units.

In addition, research groups around the world have also confirmed and expanded the physiological activity in vitro and antitumor activity in vivo of cryptoalgin and its derivatives.

Cryptoalgin stands out from a large number of candidate compounds with its outstanding anti drug activity. It was purchased by Lilly, one of the top ten pharmaceutical companies in the world, for its exclusive patent right.

In order to avoid paying Merck's huge material patent fees, Lilly had to give up the development of a natural series of cryptoalgin C-8; it could only turn to a less effective synthetic cryptoalgin c-52.
In the United States and Europe, c-52 has also conducted six clinical phase II trials, which are used in the end-stage patients with colon cancer, prostate cancer, breast cancer, non-small cell lung cancer (phase II) and ovarian cancer.

Although the tumors of these patients have developed a high degree of drug resistance, and the best existing anticancer drugs have failed to work for them, but there are still positive reactions among the patients treated with c-52 (for example, the effective rate of the patients with advanced ovarian cancer who failed in platinum treatment is 12%, and there are also other advanced patients whose condition is stable and no longer worsens, and the overall disease is alleviated and improved).

What's more, these two-stage clinical trials have proved that cryptoalgae is safe to human beings, and there is no irreversible clinical side effect or side effect damaging human organs, which greatly reduces the maximum risk in the development of new drugs. Among the hundreds of cryptoalgin derivatives covered by the patent, the one with the lowest production cost and the best anti-cancer activity is cryptoalgin C-8. All the in vivo tests conducted for different tumors have proved that the anti-tumor activity of C-8 is much better than that of c-52.

C-8 is a natural series of cryptoalgae, which is a derivative of C-1 through a simple chemical reaction. The mice inoculated with MX-1 breast cancer, TSU prostate cancer, LNCaP prostate cancer and colon-38 rectal cancer completely disappeared two weeks after administration, and even after discontinuation of the drug, the tumor did not recur, reaching the curative effect of complete cure.

Shengnuo bio PRODUCT

Best sales manager contact

About Shengnuo

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.